|Articles|August 1, 2006

Pharmaceutical Executive

  • Pharmaceutical Executive-08-01-2006
  • Volume 0
  • Issue 0

How Far We've Come

In 1981, pharma was a more innocent industry. It stood on the brink of an AIDS epidemic that science had yet to name or understand. Hazards of generics, product lifecycles, and off-label marketing lay years ahead. There were no embryonic stem cells to fight over--nor euphemisms like "overactive bladder syndrome" and "erectile dysfunction" to ease conversations or kick off ad campaigns. Who knew what awaited us? To remember--and to reflect on what shaped modern pharma--we invite you to page through the most significant events of the past quarter century.

Articles in this issue

about 20 years ago

Time Machine

about 20 years ago

Getting Better

about 20 years ago

States Curb Marketing

about 20 years ago

From the Editor: Take Your Seat

about 20 years ago

Viewpoint: In Your Words

about 20 years ago

Quiz Answers

about 20 years ago

Introduction: Pharm Exec at 25

Related to this article

Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.